ArticleBMC ophthalmology2026
Racial differences in reoperation rates following dacryocystorhinostomy.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDacryocystorhinostomy is a commonly performed procedure for nasolacrimal duct obstruction with generally favorable outcomes. However, variability in long-term success has been reported, and the role of racial and ethnic factors remains incompletely understood. This study aimed to assess differences in long-term reoperation risk following dacryocystorhinostomy across racial and ethnic groups.
methodsA retrospective multicenter cohort study was conducted using deidentified electronic health records from a global research network (2005-2025). Adult patients undergoing primary dacryocystorhinostomy were included and categorized as White, Asian, Black or African American, or Other. Patients with congenital lacrimal anomalies or malignancy were excluded. Propensity score matching was performed in a 1:1 ratio between each non-White group and White patients, adjusting for demographic characteristics, socioeconomic factors, comorbidities, prior procedures, laboratory parameters, and visit type. Time-to-event analyses were performed using Kaplan-Meier estimation, log-rank tests, and Cox proportional hazards models. The primary outcome was time to reoperation, defined as repeat dacryocystorhinostomy occurring more than 90 days after the index procedure.
resultsAfter matching, 1,820 Asian, 744 Black or African American, and 629 patients in the Other group were compared with equal numbers of White patients. Reoperation occurred in 14.0% of Asian patients versus 10.4% of White patients (hazard ratio 1.32, 95% confidence interval 1.09-1.59; P = 0.004). In the Other group, reoperation rates were 11.9% versus 9.9% (hazard ratio 1.58, 95% confidence interval 1.13-2.22; P = 0.007). Among Black or African American patients, reoperation occurred in 11.2% versus 8.6% of White patients, with no statistically significant difference (hazard ratio 1.27, 95% confidence interval 0.92-1.76; P = 0.153).
conclusionsDifferences in long-term reoperation risk following dacryocystorhinostomy were observed across racial and ethnic groups, with higher risk in Asian and Other groups compared with matched White patients. These findings are hypothesis-generating and should be interpreted in light of the absence of data on surgical technique, operative variables and socioeconomic factors. Prospective studies capturing these variables are needed to clarify underlying mechanisms and support equitable clinical practice in lacrimal surgery.
trial registrationNot applicable. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
42920125What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.